On January 29, Archivel Farma, represented by its CEO, Olga Rúe, and Dr. Pere Joan Cardona, scientific advisor to the company, participated in the annual meeting of the Tuberculosis Vaccine Initiative (TBVI), which was held in Les Diablerets (Suïssa).
The meeting reviewed the status of the various programs of global collaboration in research on vaccines for tuberculosis (TB), but there was also space to present the new strategy of the Global HIV Vaccine Enterprise and the Validate program , promoted by various British entities (University of Oxford, London School of Hygiene and Tropical Medicine, Medical Research Council and GCRF) to investigate neglected pathogens, such as Mycobacterium tuberculosis, Mycobacterium leprae, Burkholderia pseudomallei and Leishmania spp.
The participants in the meeting also reviewed the current use of vaccines in the treatment of TB and the advances that have taken place in the TB vaccines pipeline.
